253 related articles for article (PubMed ID: 25275596)
1. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe.
Cornago M; Garcia-Alberich C; Blasco-Angulo N; Vall-Llaura N; Nager M; Herreros J; Comella JX; Sanchis D; Llovera M
Cell Death Dis; 2014 Oct; 5(10):e1435. PubMed ID: 25275596
[TBL] [Abstract][Full Text] [Related]
2. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.
Brazelle W; Kreahling JM; Gemmer J; Ma Y; Cress WD; Haura E; Altiok S
PLoS One; 2010 Dec; 5(12):e14335. PubMed ID: 21179472
[TBL] [Abstract][Full Text] [Related]
4. Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors.
Lee JH; Choy ML; Ngo L; Venta-Perez G; Marks PA
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19629-34. PubMed ID: 22106282
[TBL] [Abstract][Full Text] [Related]
5. Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death.
Del Nagro CJ; Choi J; Xiao Y; Rangell L; Mohan S; Pandita A; Zha J; Jackson PK; O'Brien T
Cell Cycle; 2014; 13(2):303-14. PubMed ID: 24247149
[TBL] [Abstract][Full Text] [Related]
6. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents.
Dowling M; Voong KR; Kim M; Keutmann MK; Harris E; Kao GD
Cancer Biol Ther; 2005 Feb; 4(2):197-206. PubMed ID: 15753652
[TBL] [Abstract][Full Text] [Related]
7. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.
Havas AP; Rodrigues KB; Bhakta A; Demirjian JA; Hahn S; Tran J; Scavello M; Tula-Sanchez AA; Zeng Y; Schmelz M; Smith CL
Cancer Biol Ther; 2016 Dec; 17(12):1240-1252. PubMed ID: 27791595
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Gilardini Montani MS; Granato M; Santoni C; Del Porto P; Merendino N; D'Orazi G; Faggioni A; Cirone M
Cell Oncol (Dordr); 2017 Apr; 40(2):167-180. PubMed ID: 28160167
[TBL] [Abstract][Full Text] [Related]
10. Transformation/transcription domain-associated protein (TRRAP)-mediated regulation of Wee1.
Calonge TM; Eshaghi M; Liu J; Ronai Z; O'Connell MJ
Genetics; 2010 May; 185(1):81-93. PubMed ID: 20194963
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity.
Smith S; Fox J; Mejia M; Ruangpradit W; Saberi A; Kim S; Choi Y; Oh S; Wang Y; Choi K; Li L; Hendrickson EA; Takeda S; Muller M; Myung K
PLoS One; 2014; 9(1):e87203. PubMed ID: 24466340
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures.
Xu J; Sampath D; Lang FF; Prabhu S; Rao G; Fuller GN; Liu Y; Puduvalli VK
J Neurooncol; 2011 Nov; 105(2):241-51. PubMed ID: 21598070
[TBL] [Abstract][Full Text] [Related]
13. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
Yaseen A; Chen S; Hock S; Rosato R; Dent P; Dai Y; Grant S
Mol Pharmacol; 2012 Dec; 82(6):1030-41. PubMed ID: 22923501
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure.
Qiu X; Rong X; Yang J; Lu Y
BMC Ophthalmol; 2019 Feb; 19(1):42. PubMed ID: 30717701
[TBL] [Abstract][Full Text] [Related]
17. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
19. An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner.
Noh EJ; Lim DS; Jeong G; Lee JS
Biochem Biophys Res Commun; 2009 Jan; 378(3):326-31. PubMed ID: 19038231
[TBL] [Abstract][Full Text] [Related]
20. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]